Halberd Files Provisional Patent on Breakthrough Obesity Treatment
Halberd Corporation (OTC PINK:HALB) has filed a provisional patent application for a new process aimed at removing obesity-related proteins, cytokines, and antigens from patients' blood. This innovative approach may help alleviate severe health issues linked to obesity. The research builds on previous work in treating PTSD and Alzheimer's Disease, suggesting a potential connection between inflammatory cytokines and obesity. The treatment process is designed to be as straightforward as blood donation, with expected completion times of 30-60 minutes.
- Filed a provisional patent for a novel obesity treatment targeting proteins and cytokines.
- Research builds on existing projects for PTSD and Alzheimer's, enhancing credibility.
- Proposed treatment is user-friendly, akin to blood donation, possibly improving patient compliance.
- No immediate financial metrics or projections provided, leaving uncertainty about potential revenue.
- Forward-looking statements pose risks due to uncertainties in treatment efficacy and market acceptance.
JACKSON CENTER, PA / ACCESSWIRE / October 25, 2021 / Halberd Corporation (OTC PINK:HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity. Removal of these obesity-related target elements would reduce or eliminate the negative health issues associated with obesity.
Halberd's researchers have discovered certain inflammatory cytokines associated with PTSD and Alzheimer's Disease are also linked to the propensity for obesity when present in the blood. Halberd's work in eliminating antigens, inflammatory cytokines and excitatory neurotransmitters from Cerebral Spinal Fluid (CSF) for the treatment of PTSD, and from CSF and blood for the treatment of Alzheimer's Disease, provided the foundational work for this additional benefit relative to the treatment of obesity. It is believed that reduction of these elements could finally unlock the secret of why some people can eat anything and never seem to gain weight, while others struggle to maintain or lose weight with fad diets, pills and huge costs.
William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated "It is envisioned that the treatment process would be as simple and as easy as donating blood, and should be just as safe. In a clinical setting, the patient would have a needle inserted into a vein in their arm through which the blood would flow through the extracorporeal treatment device where the targeted elements would be cleansed from the blood before being returned to the patient's arm. The process is expected to take 30-60 minutes per treatment and, several treatments may be required to achieve the desired result. Research on this project is expected to begin immediately in parallel with Halberd's current on-going work on PTSD and Alzheimer's disease with Halberd's university partners. Far from diverting attention from our PTSD and Alzheimer's initiatives, this is merely another adaptation of our patented extracorporeal technology and its multiplicity of applications. An update on our progress will be issued as we achieve program milestones."
To get the latest news on Halberd's exciting medical developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter: @HalberdC
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to numerous patent- and PCT-pending extracorporeal treatments for COVID-19, PTSD, Alzheimer's Disease, and other medical maladies. Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/669418/Halberd-Files-Provisional-Patent-on-Breakthrough-Obesity-Treatment
FAQ
What recent patent has Halberd Corporation (HALB) filed?
How does Halberd's new treatment process work?
What diseases is Halberd Corporation focusing on alongside obesity?
What are the expected treatment times for Halberd's new obesity procedure?
How does Halberd Corporation plan to develop this treatment?
